13 results on '"Henderson, MA"'
Search Results
2. Where the streets are paved with gold
- Author
-
Henderson, Mark
- Published
- 1999
3. BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting.
- Author
-
Scolyer RA, Atkinson V, Gyorki DE, Lambie D, O'Toole S, Saw RPM, Amanuel B, Angel CM, Button-Sloan AE, Carlino MS, Ch'ng S, Colebatch AJ, Daneshvar D, Pires da Silva I, Dawson T, Ferguson PM, Foster-Smith E, Fox SB, Gill AJ, Gupta R, Henderson MA, Hong AM, Howle JR, Jackett LA, James C, Lee CS, Lochhead A, Loh D, McArthur GA, McLean CA, Menzies AM, Nieweg OE, O'Brien BH, Pennington TE, Potter AJ, Prakash S, Rawson RV, Read RL, Rtshiladze MA, Shannon KF, Smithers BM, Spillane AJ, Stretch JR, Thompson JF, Tucker P, Varey AHR, Vilain RE, Wood BA, and Long GV
- Subjects
- Australia, Biomarkers, Tumor genetics, Biomarkers, Tumor metabolism, DNA Mutational Analysis, Guidelines as Topic, Humans, Immunohistochemistry methods, Molecular Targeted Therapy, Mutation, National Health Programs, Neoplasm Staging, Proto-Oncogene Proteins B-raf metabolism, Skin Neoplasms diagnosis, Skin Neoplasms pathology, Skin Neoplasms therapy, Melanoma diagnosis, Melanoma pathology, Melanoma therapy, Proto-Oncogene Proteins B-raf genetics
- Abstract
Targeted therapy (BRAF inhibitor plus MEK inhibitor) is now among the possible treatment options for patients with BRAF mutation-positive stage III or stage IV melanoma. This makes prompt BRAF mutation testing an important step in the management of patients diagnosed with stage III or IV melanoma; one that can help better ensure that the optimal choice of systemic treatment is initiated with minimal delay. This article offers guidance about when and how BRAF mutation testing should be conducted when patients are diagnosed with melanoma in Australia. Notably, it recommends that pathologists reflexively order BRAF mutation testing whenever a patient is found to have American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) stage III or IV melanoma (i.e., any metastatic spread beyond the primary tumour) and that patient's BRAF mutation status is hitherto unknown, even if BRAF mutation testing has not been specifically requested by the treating clinician (in Australia, Medicare-subsidised BRAF
V600 mutation testing does not need to be requested by the treating clinician). When performed in centres with appropriate expertise and experience, immunohistochemistry (IHC) using the anti-BRAF V600E monoclonal antibody (VE1) can be a highly sensitive and specific means of detecting BRAFV600E mutations, and may be used as a rapid and relatively inexpensive initial screening test. However, VE1 immunostaining can be technically challenging and difficult to interpret, particularly in heavily pigmented tumours; melanomas with weak, moderate or focal BRAFV600E immunostaining should be regarded as equivocal. It must also be remembered that other activating BRAFV600 mutations (including BRAFV600K ), which account for ∼10-20% of BRAFV600 mutations, are not detected with currently available IHC antibodies. For these reasons, if available and practicable, we recommend that DNA-based BRAF mutation testing always be performed, regardless of whether IHC-based testing is also conducted. Advice about tissue/specimen selection for BRAF mutation testing of patients diagnosed with stage III or IV melanoma is also offered in this article; and potential pitfalls when interpreting BRAF mutation tests are highlighted., (Copyright © 2021 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
4. Oncologic Outcomes After Isolated Limb Infusion for Advanced Melanoma: An International Comparison of the Procedure and Outcomes Between the United States and Australia.
- Author
-
Carr MJ, Sun J, Kroon HM, Miura JT, Beasley GM, Farrow NE, Mosca PJ, Lowe MC, Farley CR, Kim Y, Naqvi SMH, Kirichenko DA, Potdar A, Daou H, Mullen D, Farma JM, Henderson MA, Speakman D, Serpell J, Delman KA, Smithers BM, Coventry BJ, Tyler DS, Thompson JF, and Zager JS
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Australia, Chemotherapy, Cancer, Regional Perfusion, Extremities, Female, Humans, Male, Melphalan therapeutic use, United States, Melanoma drug therapy, Skin Neoplasms drug therapy
- Abstract
Background: Isolated limb infusion (ILI) is a minimally invasive procedure for delivering high-dose chemotherapy to extremities affected by locally advanced or in-transit melanoma. This study compared the outcomes of melanoma patients treated with ILI in the United States of America (USA) and Australia (AUS)., Methods: Patients with locally recurrent in-transit melanoma treated with ILI at USA or AUS centers between 1992 and 2018 were identified. Demographic and clinicopathologic characteristics were collected. Primary outcomes of treatment response, in-field progression-free survival (IPFS), distant progression-free survival (DPFS), and overall survival (OS) were evaluated by the Kaplan-Meier method. Multivariable analysis evaluated whether availability of new systemic therapies affected outcomes., Results: More ILIs were performed in AUS (n = 411, 60 %) than in the USA (n = 276, 40 %). In AUS, more ILIs were performed for stage 3B disease than in the USA (62 % vs 46 %; p < 0.001). The reported complete response rates were similar (AUS 30 % vs USA 29 %). Among the stage 3B patients, AUS patients had better IPFS (p = 0.001), whereas DPFS and OS were similar between the two countries. Among the stage 3C patients, the USA patients had better OS (p < 0.001), whereas IPFS and DPFS were similar. Availability of new systemic therapies did not affect IPFS or DPFS in either country. However, the USA patients who received ILI after ipilimumab approval in 2011 had significantly improved OS (hazard ratio, 0.62; p = 0.013)., Conclusions: AUS patients were treated at an earlier disease stage than the USA patients with better IPFS for stage 3B disease. The USA patients treated after the availability of new systemic therapies had a better OS.
- Published
- 2020
- Full Text
- View/download PDF
5. Factors predicting toxicity and response following isolated limb infusion for melanoma: An international multi-centre study.
- Author
-
Kenyon-Smith TJ, Kroon HM, Miura JT, Teras J, Beasley GM, Mullen D, Farrow NE, Mosca PJ, Lowe MC, Farley CR, Potdar A, Daou H, Sun J, Farma JM, Henderson MA, Speakman D, Serpell J, Delman KA, Smithers BM, Barbour A, Coventry BJ, Tyler DS, Zager JS, and Thompson JF
- Subjects
- Age Factors, Aged, Aged, 80 and over, Amputation, Surgical, Australia, Creatine Kinase metabolism, Dactinomycin administration & dosage, Dose-Response Relationship, Drug, Female, Humans, Ischemia etiology, Ischemia metabolism, Lower Extremity, Male, Melanoma pathology, Melphalan administration & dosage, Middle Aged, Neoplasm Metastasis, Sex Factors, Skin Neoplasms pathology, Time Factors, Tourniquets, United States, Upper Extremity, Antineoplastic Combined Chemotherapy Protocols adverse effects, Chemotherapy, Cancer, Regional Perfusion adverse effects, Melanoma drug therapy, Skin Neoplasms drug therapy
- Abstract
Introduction: Isolated limb infusion (ILI) is a minimally-invasive procedure for delivering high-dose regional chemotherapy to treat melanoma in-transit metastases confined to a limb. The aim of this international multi-centre study was to identify predictive factors for toxicity and response., Methods: Data of 687 patients who underwent a first ILI for melanoma in-transit metastases confined to the limb between 1992 and 2018 were collected at five Australian and four US tertiary referral centres., Results: After ILI, predictive factors for increased limb toxicity (Wieberdink grade III/IV limb toxicity, n = 192, 27.9%) were: female gender, younger age, procedures performed before 2005, lower limb procedures, higher melphalan dose, longer drug circulation and ischemia times, and increased tissue hypoxia. No patient experienced grade V toxicity (necessitating amputation). A complete response (n = 199, 28.9%) was associated with a lower stage of disease, lower burden of disease (BOD) and thinner Breslow thickness of the primary melanoma. Additionally, an overall response (combined complete and partial response, n = 441, 64.1%) was associated with female gender, Australian centres, procedures performed before 2005, lower limb procedures and lower actinomycin-D doses. On multivariate analysis, higher melphalan dose remained a predictive factor for toxicity, while lower stage of disease and lower BOD remained predictive factors for overall response., Conclusion: ILI is safe and effective to treat melanoma in-transit metastases. Predictive factors for toxicity and response identified in this study will allow improved patient selection and optimization of intra-operative parameters to increase response rates, while keeping toxicity low., Competing Interests: Declaration of competing interest None., (Copyright © 2020 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
6. Radiation-Associated Thyroid Cancer Surveillance and Management in a Cohort of Late Effects Patients.
- Author
-
Koo E, Henderson MA, Dwyer M, and Skandarajah AR
- Subjects
- Adolescent, Adult, Australia, Biopsy, Fine-Needle, Child, Child, Preschool, Cohort Studies, Female, Humans, Image-Guided Biopsy, Infant, Male, Middle Aged, Neoplasms, Radiation-Induced pathology, Neoplasms, Radiation-Induced therapy, Thyroid Neoplasms pathology, Thyroid Neoplasms therapy, Ultrasonography, Interventional, Young Adult, Neoplasms, Radiation-Induced epidemiology, Thyroid Neoplasms epidemiology
- Abstract
Background and Aims: Compared to the general population, the incidence of thyroid cancer in childhood and adolescent and young adult malignancy survivors is increased 14.0-18.0 times (CI 11.7-23.8). The cumulative incidence is variably reported as 0.5% by age 45 with 30-year incidence of 1.3% in women and 0.6% in men. This study aims to evaluate the incidence of radiation-associated thyroid cancer amongst patients treated with prior radiation to the thyroid followed up in a late effects service. A secondary aim was to assess screening compliance in this cohort., Methods: The medical records of all patients attending the late effects service from 1 January 2000 to 20 February 2013 were interrogated to identify patients exposed to thyroid irradiation. The screening compliance and incidence of thyroid cancer were assessed for the duration whilst under the guidance of the late effect service. Mode of diagnosis, all imaging and cytology were retrieved from the institutional electronic record. Cytology was categorized according to Bethesda., Results: Four hundred and sixty-five patients were exposed to direct or scatter neck irradiation. Compliance with thyroid surveillance was observed in 76.9%. Ultrasound features of microcalcification and increased internal vascularity had a low sensitivity (62.5%) for predicting a malignant nodule, which improved when used in conjunction with a Bethesda IV-VI result (91.7%). However, cytological assessment was not performed in 45.6% of operative cases. Thirty-three patients had thyroid carcinoma of which 45.4% (n = 15) were incidental. The majority were papillary thyroid cancers (88.9%); of which 12.5% were node positive and 34.4% were multifocal. The incidence of thyroid cancer was elevated 57.6 times compared to the Australian general population (p < 0.001)., Conclusion: Due to the high incidence of thyroid cancer, this study supports screening in this cohort. However, due to the risk of overtreatment, we endorse further investigation of thyroid nodules with ultrasound-guided fine-needle aspiration cytology based on sonographic criteria as for the general population and American Thyroid Association guidelines.
- Published
- 2020
- Full Text
- View/download PDF
7. International Multicenter Experience of Isolated Limb Infusion for In-Transit Melanoma Metastases in Octogenarian and Nonagenarian Patients.
- Author
-
Teras J, Kroon HM, Miura JT, Kenyon-Smith T, Beasley GM, Mullen D, Farrow NE, Mosca PJ, Lowe MC, Farley CR, Potdar A, Daou H, Sun J, Carr M, Farma JM, Henderson MA, Speakman D, Serpell J, Delman KA, Smithers BM, Barbour A, Tyler DS, Coventry BJ, Zager JS, and Thompson JF
- Subjects
- Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols adverse effects, Australia, Dactinomycin administration & dosage, Female, Humans, Length of Stay, Lower Extremity, Male, Melanoma pathology, Melanoma secondary, Melphalan administration & dosage, Neoplasm Metastasis, Neoplasm Staging, Neoplasm, Residual, Progression-Free Survival, Skin Neoplasms pathology, Skin Neoplasms secondary, Treatment Outcome, Tumor Burden, United States, Upper Extremity, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Chemotherapy, Cancer, Regional Perfusion methods, Melanoma drug therapy, Skin Neoplasms drug therapy
- Abstract
Background: Isolated limb infusion (ILI) is used to treat in-transit melanoma metastases confined to an extremity. However, little is known about its safety and efficacy in octogenarians and nonagenarians (ON)., Patients and Methods: ON patients (≥ 80 years) who underwent a first ILI for American Joint Committee on Cancer seventh edition stage IIIB/IIIC melanoma between 1992 and 2018 at nine international centers were included and compared with younger patients (< 80 years). A cytotoxic drug combination of melphalan and actinomycin-D was used., Results: Of the 687 patients undergoing a first ILI, 160 were ON patients (median age 84 years; range 80-100 years). Compared with the younger cohort (n = 527; median age 67 years; range 29-79 years), ON patients were more frequently female (70.0% vs. 56.9%; p = 0.003), had more stage IIIB disease (63.8 vs. 53.3%; p = 0.02), and underwent more upper limb ILIs (16.9% vs. 9.5%; p = 0.009). ON patients experienced similar Wieberdink limb toxicity grades III/IV (25.0% vs. 29.2%; p = 0.45). No toxicity-related limb amputations were performed. Overall response for ON patients was 67.3%, versus 64.6% for younger patients (p = 0.53). Median in-field progression-free survival was 9 months for both groups (p = 0.88). Median distant progression-free survival was 36 versus 23 months (p = 0.16), overall survival was 29 versus 40 months (p < 0.0001), and melanoma-specific survival was 46 versus 78 months (p = 0.0007) for ON patients compared with younger patients, respectively., Conclusions: ILI in ON patients is safe and effective with similar response and regional control rates compared with younger patients. However, overall and melanoma-specific survival are shorter.
- Published
- 2020
- Full Text
- View/download PDF
8. New treatment paradigms for clinically apparent metastatic melanoma in regional lymph nodes.
- Author
-
Henderson MA, Spillane J, Hughes TM, Spillane AJ, Smithers BM, and Thompson JF
- Subjects
- Australia epidemiology, Biopsy, Fine-Needle methods, Humans, Immunotherapy adverse effects, Immunotherapy methods, Lymph Nodes surgery, Neoplasm Recurrence, Local surgery, Neoplasm Staging methods, Practice Guidelines as Topic, Sentinel Lymph Node Biopsy methods, Lymph Nodes pathology, Melanoma secondary, Skin Neoplasms pathology
- Published
- 2019
- Full Text
- View/download PDF
9. Evaluation of the efficacy and toxicity of upper extremity isolated limb infusion chemotherapy for melanoma: An Australian multi-center study.
- Author
-
Kroon HM, Coventry BJ, Henderson MA, Barbour A, Serpell J, Smithers BM, and Thompson JF
- Subjects
- Aged, Aged, 80 and over, Antibiotics, Antineoplastic administration & dosage, Antineoplastic Agents, Alkylating administration & dosage, Australia, Chemotherapy, Cancer, Regional Perfusion adverse effects, Dactinomycin administration & dosage, Female, Humans, Lymph Node Excision, Lymphatic Metastasis, Male, Melanoma pathology, Melphalan administration & dosage, Middle Aged, Prospective Studies, Skin Neoplasms pathology, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Chemotherapy, Cancer, Regional Perfusion methods, Melanoma drug therapy, Skin Neoplasms drug therapy, Upper Extremity
- Abstract
Background: Isolated limb infusion (ILI) is a minimally invasive treatment for patients with locally advanced extremity melanoma. Most studies combine results of upper-limb ILI (UL-ILI) and lower-limb ILI (LL-ILI), leaving UL-ILIs relatively underreported as LL-ILIs comprise the vast majority in these reports. However, differences between the two procedures may be clinically important. The aim of this study was to evaluate the efficacy and toxicity of UL-ILI in an Australian multi-center setting., Patients and Methods: 316 ILI procedures for melanoma performed between 1992 and 2008 in five Australian institutions were analyzed. In all institutions melphalan (±actinomycin D) was circulated in the isolated limb for 20-30 min., Results: Baseline patient characteristics for UL-ILI (n = 27) and LL-ILI (n = 289) were similar, except that more men underwent UL-ILI (66% vs. 38%; p = 0.007) and disease in LL-ILI was mostly located on the distal limb (p = 0.02). Median tourniquet times were shorter for UL-ILI (38 vs. 48 min; p = 0.04) and UL-ILI patients experienced less limb toxicity (Grade III/IV in 24% vs. 31%; p = 0.01). Complete response (CR) rates were similar: 33% after LL-ILI (p = 0.70), 30% after UL-ILI, while overall response (OR) rates were higher after LL-ILI: (76%) than UL-ILI (59%; p = 0.05). No difference in survival was seen., Conclusions: UL-ILI is safe to perform and effective, resulting in low limb toxicity. CR rates were similar to those for LL-ILI, but OR rates were lower for UL-ILI. It may be possible to improve OR rates achieved by UL-ILI by optimizing perioperative factors, while maintaining low toxicity., (Copyright © 2019 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
10. Improving care for patients with melanoma.
- Author
-
Spillane JB and Henderson MA
- Subjects
- Australia, Humans, Melanoma diagnosis, Melanoma pathology, Neoplasm Staging, New Zealand, Melanoma therapy, Patient Care standards, Practice Guidelines as Topic, Quality Improvement
- Published
- 2012
- Full Text
- View/download PDF
11. The management of primary cutaneous melanoma in Victoria in 1996 and 2000.
- Author
-
Kelly JW, Henderson MA, Thursfield VJ, Slavin J, Ainslie J, and Giles GG
- Subjects
- Aged, Australia epidemiology, Biopsy methods, Biopsy statistics & numerical data, Continuity of Patient Care statistics & numerical data, Female, Humans, Male, Melanoma epidemiology, Melanoma pathology, Middle Aged, Neoplasm Invasiveness, Registries, Skin pathology, Skin Neoplasms epidemiology, Skin Neoplasms pathology, Surveys and Questionnaires, Melanoma surgery, Skin Neoplasms surgery
- Abstract
Objective: To describe tumour characteristics and clinical management of melanomas newly diagnosed in 1996 and in 2000--before and after publication of the clinical practice "Guidelines for the management of cutaneous melanoma" by the Australian Cancer Network (1997), and their endorsement by the National Health and Medical Research Council (NHMRC) and republication (1999)., Design and Setting: Survey of clinicians involved in the management of patients with melanoma sampled from the Victorian Cancer Registry. The Registry is notified of all cases of cancer diagnosed by pathology laboratories and hospitals in both the public and private health sectors in the state of Victoria., Patients: People with a cutaneous melanoma newly diagnosed in 1996 and 2000. All invasive melanomas > 1.50 mm in thickness were included, and for each year random samples were selected of 100 each of invasive melanomas 0.76-1.50 mm in thickness, invasive melanomas < or = 0.75 mm, and in-situ melanomas, plus 50 melanomas of unknown thickness., Main Outcome Measures: Biopsy method, adequacy of pathology reporting, adequacy of definitive excision (compared with margins recommended by the Guidelines), and follow-up procedures., Results: The use of partial biopsies increased between 1996 and 2000. Recommended margins of definitive excision were used in only 33.6% of cases. Margins were smaller than recommended for 36% of in-situ melanomas, risking recurrence of primary melanoma. Documented follow-up examinations for subsequent primary skin malignancy were uncommon (6%)., Conclusions: Many aspects of the management of primary cutaneous melanoma appear not to meet the recommendations of the published Guidelines. Further studies to explore the reasons for failure to meet the Guideline recommendations are needed.
- Published
- 2007
- Full Text
- View/download PDF
12. Clinical, pathological and genetic features of women at high familial risk of breast cancer undergoing prophylactic mastectomy.
- Author
-
Scott CI, Iorgulescu DG, Thorne HJ, Henderson MA, and Phillips KA
- Subjects
- Australia, Breast Neoplasms surgery, Cohort Studies, Demography, Female, Genes, BRCA1, Genes, BRCA2, Genetic Testing, Humans, Risk Assessment, Breast Neoplasms genetics, Breast Neoplasms prevention & control, Genetic Predisposition to Disease, Mastectomy
- Abstract
Prophylactic mastectomy (PM) is a risk-management option for women at high familial risk of breast cancer (BC). This study describes the PM experience of women enrolled in a large observational cohort study involving families with a history of hereditary breast cancer. Within 357 multiple-case BC families [119 (33%) BRCA1 or BRCA2 mutation positive], identified via family cancer clinics, 49 cases of PM [21 (43%) BRCA1 or BRCA2 mutation positive] were identified and their clinical, pathological and genetic features reviewed. Families with at least one incidence of PM displayed stronger breast/ovarian cancer histories than did families without PM. Median age at time of PM was 45 years (range 28-58). Ten cases (21%) were bilateral PMs in unaffected women and 39 cases were contralateral PMs in women with prior invasive BC (71%) or ductal carcinoma in situ (DCIS) (8%). Most (88%) underwent total mastectomy. Unnecessary axillary surgery occurred in eight subjects (16%). Malignant histology was found in three PM specimens (6%). Prior to genetic testing, PM was performed in two women who were subsequently shown not to carry the mutation specific to their family. Optimal utilization of genetic testing to guide surgical decision making, appropriate surgical technique and careful pathology examination of PM specimens, are important issues to consider prior to PM in women at high familial risk of BC.
- Published
- 2003
- Full Text
- View/download PDF
13. Breast cancer in the elderly: pattern of disease.
- Author
-
Hainsworth PJ, Henderson MA, and Bennett RC
- Subjects
- Aged, Aged, 80 and over, Australia, Breast Neoplasms mortality, Breast Neoplasms pathology, Female, Humans, Incidence, Male, Neoplasm Staging, Neoplasms, Second Primary epidemiology, Survival Rate, Breast Neoplasms epidemiology
- Abstract
The elderly (aged 70 years or more) constituted 201 (37%) of 548 first-time admissions to a single institution for breast cancer between 1976 and 1985. The pattern of disease was studied and contrasted with that seen in younger patients (less than 70 years old). Currently, 5000 new breast cancers are diagnosed in Australia each year. It is projected that the proportion of new breast cancer patients who are elderly will rise from 37 to 60% by the year 2031. In general, the disease was similar to that seen in younger patients. Minor histological differences occurred and there were tendencies towards late presentation and clinically less aggressive disease. Tumour size, the presence of metastases and UICC staging were useful predictors of outcome but nodal status and hormone receptor levels did not discriminate. An unexpected finding was the relative longevity of elderly patients with breast cancer. The stage-specific 5-year survival rates (UICC stages: I--73%; II--65%; III--42%; IV--10%;) did not differ significantly from those seen in younger patients.
- Published
- 1991
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.